Adam Lerner, MD
Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology

MD, Yale University School of Medicine



Expertise includes: CLL; Leukemia; Lymphoid malignancies; Sarcoma; Breast cancer; cAMP signaling.

Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Division of Graduate Medical Sciences


Professor
Boston University School of Medicine
Pathology & Laboratory Medicine


Active Staff Privileges
Boston Medical Center
Medicine
Hematology & Medical Oncology


2008-2013 NHLBI Award
2005-2010 NCI RO1 Awards
2001-2004 DOD Breast Cancer Idea Award
1998-2001 American Society of Clinical Oncology: Career Development Award
1997-1998 American Cancer Society: Research Award
1997-1999 Translational Research Award: Leukemia Society of America
1992-1995 Special Fellowship: 5 Leukemia Society of America
200-2004 NCI RO1 Award


A randomized, open-label, phase 3 trial of Brentuximab vedotin (SGN-35) versus physician's choice (Methotrexate or Bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma
08/10/2012 - 08/10/2019 (PI)
Millennium Pharmaceuticals, Inc.


Research Training in Blood Diseases and Resources
06/01/2014 - 05/31/2019 (Co-PI)
PI: Martin H. Steinberg, MD
NIH/National Heart, Lung, and Blood Institute
5T32HL007501-36

Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma
02/03/2014 - 02/02/2019 (PI)
Kyowa Hakko Kirin Pharma, Inc.


Personnel Agreement for Research Services of Deborah Govan
01/01/2013 - 01/28/2016 (PI)
VA Boston Healthcare System


Research Training in Blood Diseases and Resources
09/19/2008 - 05/31/2014 (PI)
NIH/National Heart, Lung, and Blood Institute
5T32HL007501-31

Access Program with Denileukin diftitox for the treatment of patients currently receiving treatment with commercially available Ontak
11/01/2011 - 10/31/2012 (PI)
Eisai Medical Research Institute, Inc.


A Phase III Study of Taxoprexin Injection vs. Dacarbazine in Patients with Metastatic Malignant Melanoma
03/27/2006 - 03/26/2008 (PI)
CuraGen Corporation

The National Lymphocare Study: An Observational Study of Treatment, Outcomes, and Prognosis in Patients with Follicular Non-Hodgkin’s Lymphoma
11/03/2005 - 11/02/2007 (PI)
Genentech, Inc.

A Phase III Study of Taxoprexin Injection vs. Dacarbazine in Patients with Metastatic Malignant Melanoma
12/23/2005 - 12/31/2006 (PI)
Luitpold Pharmaceuticals, Inc.

Open-label, Dose Escalation, Followed by Double-blind, Randomized, Two-dose, Parallel Group, Multi-center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with
06/02/2005 - 06/01/2006 (PI)
Genmab Inc.


Showing 10 of 14 results. Show All Results



Yr Title Project-Sub Proj Pubs
2018 Research Training in Blood Diseases and Resources 5T32HL007501-36 74
2016 Research Training in Blood Diseases and Resources 5T32HL007501-34 74
2014 Research Training in Blood Diseases and Resources 2T32HL007501-32 74
2012 Research Training in Blood Diseases and Resources 5T32HL007501-31 74
2011 EFFECT OF PHOSPHORYLATION ON INTERACTION OF P130CAS WITH AND-34 5P41RR010888-15-5136 236
2011 Research Training in Blood Diseases and Resources 5T32HL007501-30 74
2010 EFFECT OF PHOSPHORYLATION ON INTERACTION OF P130CAS WITH AND-34 5P41RR010888-14-6841 236
2010 Research Training in Blood Diseases and Resources 5T32HL007501-29 74
2009 EFFECT OF PHOSPHORYLATION ON INTERACTION OF P130CAS WITH AND-34 5P41RR010888-13-6196 236
2009 Cyclic AMP-mediated apoptosis in lymphoid malignancies 5R01CA106705-05 5
Showing 10 of 28 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Min MS, Al-Haseni A, Succaria F, Goldberg L, Lerner A, Sahni D. Anaplastic large cell lymphoma localized to the left breast years after radiotherapy for breast cancer. Dermatol Online J. 2018 Jan 15; 24(1).View Related Profiles. PMID: 29469762.
     
  2. de Medeiros AS, Wyman AR, Alaamery MA, Allain C, Ivey FD, Wang L, Le H, Morken JP, Habara A, Le C, Cui S, Lerner A, Hoffman CS. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays. Cell Signal. 2017 Dec; 40:73-80.View Related Profiles. PMID: 28867658.
     
  3. Duvic M, Bates SE, Piekarz R, Eisch R, Kim YH, Lerner A, Robak T, Samtsov A, Becker JC, McCulloch W, Waksman J, Whittaker S. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leuk Lymphoma. 2018 Apr; 59(4):880-887. PMID: 28853310.
     
  4. Foss F, Duvic M, Lerner A, Waksman J, Whittaker S. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. Clin Lymphoma Myeloma Leuk. 2016 Nov; 16(11):637-643. PMID: 27637428; DOI: 10.1016/j.clml.2016.08.009;.
     
  5. Xu C, Wyman AR, Alaamery MA, Argueta SA, Ivey FD, Meyers JA, Lerner A, Burdo TH, Connolly T, Hoffman CS, Chiles TC. Anti-inflammatory effects of novel barbituric acid derivatives in T lymphocytes. Int Immunopharmacol. 2016 Sep; 38:223-32.View Related Profiles. PMID: 27302770; DOI: 10.1016/j.intimp.2016.06.004;.
     
  6. Dong H, Carlton ME, Lerner A, Epstein PM. Effect of cAMP signaling on expression of glucocorticoid receptor, Bim and Bad in glucocorticoid-sensitive and resistant leukemic and multiple myeloma cells. Front Pharmacol. 2015; 6:230. PMID: 26528184; DOI: 10.3389/fphar.2015.00230;.
     
  7. Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Waksman J, Whittaker S. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma. 2015; 56(10):2847-54. PMID: 25791237; PMCID: PMC4732431; DOI: 10.3109/10428194.2015.1014360;.
     
  8. Tan Y, Watkins AA, Freeman BB, Meyers JA, Rifkin IR, Lerner A. Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells. J Immunol. 2015 Jan 1; 194(1):101-12.View Related Profiles. PMID: 25416804; PMCID: PMC4333002.
     
  9. Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015 Mar; 168(6):811-9. PMID: 25404094; DOI: 10.1111/bjh.13222;.
     
  10. Foss F, Coiffier B, Horwitz S, Pro B, Prince HM, Sokol L, Greenwood M, Lerner A, Caballero D, Baran E, Kim E, Nichols J, Balser B, Wolfson J, Whittaker S. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomark Res. 2014; 2:16. PMID: 25279222; DOI: 10.1186/2050-7771-2-16;.
     
Showing 10 of 73 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 70 publications over 27 distinct years, with a maximum of 6 publications in 2007 and 2009

YearPublications
19882
19891
19924
19932
19941
19962
19971
19982
19992
20002
20011
20023
20035
20042
20053
20063
20076
20081
20096
20101
20115
20123
20144
20153
20162
20172
20181
Contact for Mentoring:


650 Albany St Evans Biomed Research Ctr
Boston MA 02118
Google Map


Lerner's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department